BioCentury
ARTICLE | Company News

AbbVie, Bristol-Myers, Merck, Pfizer, Roche, UCB sales and marketing update

February 1, 2016 8:00 AM UTC

The U.K.’s NICE issued final guidance recommending seven drugs in combination with methotrexate to treat severe rheumatoid arthritis (RA) in patients whose disease has not responded to previous, intensive therapy -- their approved indications. The drugs are Humira adalimumab from AbbVie, Enbrel etanercept from Pfizer, Remicade infliximab from Merck, Cimzia certolizumab from UCB, Simponi golimumab from Merck, RoActemra tocilizumab from Roche and Orencia abatacept from Bristol-Myers Squibb. Humira, Enbrel, Cimzia and RoActemra may be taken as monotherapy in methotrexate intolerant patients or in patients when methotrexate is contraindicated. The guidance is in line with final draft recommendations (see BioCentury, Sept. 21, 2015). ...